Genetic Susceptibility to Severe Streptococcal Infections
NCT ID: NCT01911572
Last Updated: 2018-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2013-12-31
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
As individuals vary greatly in their risk of developing such serious infections, investigating how the genome, the inherited blueprint of our bodies, of these patients differs from that of healthy volunteers can help to explain why the disease develops in some and not others. For some streptococcal bacteria such as Streptococcus pneumoniae this approach is already proving successful; for others such as the "Group A" strain (Streptococcus pyogenes) it has yet to be explored but carries excellent potential.
The investigators have secured the support of the Lee Spark Necrotising Fasciitis Foundation to recruit from their membership survivors of streptococcal infections and some of their family members. The investigators will also ask infection specialists from NHS hospitals to invite patients they have looked after. The investigators also have a small existing collection. Taking part would involve registering information on a website, discussing the study on the telephone and then providing us with a sample of saliva from which the investigators can isolate DNA. The investigators would prepare the sample for analysis of the genome and compare the patients with both their family and an existing reference collection from healthy volunteers using technology that reads the DNA code.
Our study will be a first key step in renewing efforts to understand the determinants of invasive streptococcal infection, which is important for developing better treatments and vaccines.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Development of a Serocorrelate of Protection Against Invasive Group B Streptococcus Disease
NCT04735419
Invasive Group A Streptococcal Infection
NCT05788861
Invasive Group A Streptococcus (GAS) Infection in Children: Bacterial Virulence Factors and Detection of Host Immunological and/or Genetic Factors of Predisposition to Infections
NCT02010294
The Association of Gene Polymorphisms With Invasive Bacterial Infections in Neonates and Young Infants
NCT06985160
Association Between a Mother's Exposure to "Strep Throat" and Her Baby's Developing Heart Disease
NCT01603732
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
FAMILY_BASED
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Survivors
Individuals who have previously experienced an episode of invasive streptococcal infection or necrotising fasciitis.
No interventions assigned to this group
Family members
Parents of those survivors aged less than forty years without risk factors for streptococcal disease (forming mother-father-child trios), or first and second degree relatives of survivors from a family in which two or more individuals have been affected.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Cases/Survivors
A. All Cases (survivors in pedigree, trio or as simplex case; existing serum samples from Imperial College London collection)
* Either of:
* Isolation of Streptococcus species from a normally sterile site (e.g. blood, joint fluid, etc.) during an acute illness since 1st January 1980
* Severe clinical presentation - streptococcal toxic shock, necrotising fasciitis, pneumonia, puerperal sepsis, meningitis - since 1st January 1980 plus concurrent Streptococcus species isolated from non-sterile site (e.g. abscess, wound swab, pus)
* And:
* Admitted to an NHS hospital in England or Wales or Northern Ireland
B. Trio case (survivor in trio)
* All of:
* Meets criteria for 1A
* Less than 40 years of age at the time of illness
* None of at the time of the illness: heart disease, diabetes mellitus, cancer, steroid use, chronic lung disease, immunocompromise, intravenous drug use and alcoholism
* Plus one of:
* More than one episode of illness meeting criteria for 1A
* Admission to high dependency or intensive care unit
* Requirement for surgical procedure (including drainage of abscess or collection)
* And:
* Both parents alive at time of recruitment
2. Unaffected phenotype family member in multi-case pedigree
* All of:
* Biological first or second degree relative of a survivor meeting criteria 1A in a family in which two or more members meet those criteria
* None of: severe streptococcal illness requiring hospital illness, recurrent tonsillitis or recurrent impetigo (recurrent is defined as more than one episode in two consecutive years)
3. Intermediate phenotype family member in multi-case pedigree
* All of:
* Biological first or second degree relative of a survivor meeting criteria 1A in a family in which two or more members meet those criteria
* History of severe bacterial illness requiring hospital admission, recurrent tonsillitis or recurrent impetigo (recurrent is defined as more than one episode in two consecutive years)
4. Parent in mother-father-child trio
* All of:
* Biological parent of case meeting criteria for 1B
* None of: severe bacterial illness requiring hospital admission, recurrent tonsillitis or recurrent impetigo (recurrent is defined as more than one episode in two consecutive years)
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Public Health England
OTHER_GOV
Imperial College London
OTHER
University of Oxford
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tom Parks, BA MB BChir MRCP DTM&H
Role: PRINCIPAL_INVESTIGATOR
University of Oxford
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Oxford Wellcome Trust Centre for Human Genetics
Oxford, Oxon, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GENIGASUK
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.